Breaking News

Dow Chemical, Cambrex in HPMCAS Pact

Cambrex to manufacture excipient for solubility enhancement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cambrex and The Dow Chemical Company have entered an agreement for Cambrex to manufacture Dow’s Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for drug solubility enhancement.   This represents the final step in solubility partnership that Dow and Bend Research announced in October 2012 and it will help Dow to commercially supply solubility enabling excipients. Construction has begun on the new operational facility at Cambrex Karlskoga and commercial product availability is set for yea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters